CDC, FDA end pause on use of Johnson & Johnson Covid-19 vaccine, following review

Federal health officials from the Centers for Disease Control and Prevention and the Food and Drug Administration on Friday evening ended a pause on the use of the Johnson & Johnson COVID-19 vaccine, following an 11-day review by a panel of experts. 

"We have concluded that the known and potential benefits of the Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older," acting FDA Commissioner Janet Woodcock said in a statement. "We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality."

Officials recently paused the use of vaccine following a small percentage of patients having gotten blood clots.